Our previous study on subcutaneous PDAC tumors using a chemotherapy‐free EGFR targeted PDT construct alluded to the fact that molecular targeted PDT modulates tumor collagen fractional area (Masson's Trichrome staining).[14] A central point of focus of this study was the evaluation of the impact that combined molecular targeted PDT and irinotecan chemotherapy using the single TPMIL construct had on desmoplasia and survival in an orthotopic heterotypic PDAC model. The gene discussed is EGFR; the disease is neoplasm.